The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 39 results
Sort by date: Descending
Encores: Not included
US Psych Congress Annual
October 29th – November 2nd 2024
Schizophrenia
POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

View poster
Schizophrenia
Schizophrenia
POSTER
Clinical Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Patients Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane, MD,1 Andrea B. Barthel, MS,2 Chenxue Liang,2 Zhengfan Wang,2 Elizabeth S. Nagelhout,2 Lauren N. Strand, PhD, MS,3 Michael J. Doane, PhD,3 Regina Grebla, PhD3

View poster
Schizophrenia
Schizophrenia
POSTER
Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
AUTHOR(S)

John M. Kane, MD1 ; Martin Dunbar, PhD2 ; and James A. McGrory, PhD2

View poster
Schizophrenia
Schizophrenia
POSTER
Acute and Maintenance Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Acute Schizophrenia: A Post Hoc Analysis
AUTHOR(S)

Roger S. McIntyre,1 Desiree M. Matthews,2 Marni E. Harris,3 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Study Retention Rates in the OLZ/SAM Phase 3 Clinical Program
AUTHOR(S)

René S. Kahn,1 Christina Arevalo,2 Marni E. Harris,2 David McDonnell3

View poster
Bipolar Disorder
Schizophrenia
Academy of Managed Care Pharmacy Nexus 2024
October 14th – 17th 2024
Sleep-wake disorders
POSTER
Clinical, Economic, and Humanistic Burden Associated With Narcolepsy: Results From a Systematic Literature Review
AUTHOR(S)

Michael J. Doane,1 Miranda Lauher-Charest,2 Gia Huynh,2 Kristen McCausland2

View poster
Sleep-wake disorders